嵌合外溶素P128治疗小鼠耐药金黄色葡萄球菌菌血症的疗效
本研究在小鼠菌血症模型中评估重组嵌合外溶素P128单用及与万古霉素或达托霉素联用的疗效。P128单药对MRSA菌血症的生存率为31%,与万古霉素或达托霉素联用分别提高到85%和88%,并快速降低腹腔液和血液中的细菌载量。P128还能恢复VRSA对万古霉素的敏感性。
要点
- P128单药对MRSA菌血症小鼠生存率为31%,与万古霉素或达托霉素联用分别升至85%和88%。
- P128在1小时内快速降低腹腔液和血液中的细菌载量。
- P128联合万古霉素使VRSA菌血症小鼠生存率从37%提高到63%。
核心结论
- P128在体内发挥快速杀菌作用,可挽救致死性侵袭性MRSA和VRSA感染小鼠。
- P128与标准治疗抗生素联用产生协同效应,并恢复VRSA对万古霉素的敏感性。
研究设计与样本
- 健康BALB/c小鼠腹腔接种109 cfu的MRSA菌株COL或USA300,单次给予P128(0.2-10 mg/kg)治疗。
- 联用试验使用单次P128(0.2或2.5 mg/kg)联合亚治疗剂量万古霉素(27.5或55 mg/kg)或达托霉素(12.5 mg/kg)。
- VRSA菌血症试验使用P128/万古霉素联合,并与小鼠等效治疗剂量万古霉素(110 mg/kg)比较。
主要发现
- MRSA菌血症中,P128、万古霉素和达托霉素单药治疗生存率分别为31%、46%和46%。
- P128/万古霉素和P128/达托霉素联合治疗生存率分别为85%和88%。
- P128在1小时内降低腹腔液和血液中的cfu。
- VRSA菌血症中,万古霉素110 mg/kg未能挽救动物,P128(1-20 mg/kg)单药呈剂量依赖性疗效。
- 2.5 mg/kg P128单药生存率为37%,联合万古霉素后升至63%。
临床怎么用
- P128可作为耐药金黄色葡萄球菌系统性感染的潜在新型治疗药物。
- P128与万古霉素或达托霉素联用可能增强疗效并恢复VRSA对万古霉素的敏感性。
局限性
- 研究仅在小鼠模型中进行,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: P128 is a recombinant chimeric ectolysin with potent antistaphylococcal activity. P128 was evaluated as monotherapy and in combination with two standard-of-care (SoC) antibiotics, vancomycin and daptomycin, in mouse models of Staphylococcus aureus bacteraemia. METHODS: Healthy BALB/c mice were challenged (intraperitoneally) with 109 cfu of MRSA strain COL or USA300 and treated with a single dose of P128 (0.2-10 mg/kg). Drug synergy was tested using a single dose of P128 (0.2 or 2.5 mg/kg) along with sub-therapeutic dose levels of vancomycin (27.5 or 55 mg/kg) or daptomycin (12.5 mg/kg). Bacterial load was checked in peritoneal fluid and in blood, at different time intervals. Synergy against drug-resistant strains was tested using the P128/vancomycin combination against vancomycin-resistant S. aureus (VRSA). RESULTS: In MRSA bacteraemia, P128, vancomycin and daptomycin monotherapy resulted in 31%, 46% and 46% survival, respectively. The P128/vancomycin and P128/daptomycin combinations afforded increased survival of 85% and 88%, respectively. P128 showed a rapid bactericidal effect with a reduction of cfu in both the peritoneal fluid and the blood within 1 h. In VRSA bacteraemia, a mouse-equivalent therapeutic dose of vancomycin (110 mg/kg) failed to rescue animals. P128 (1-20 mg/kg) as monotherapy resulted in dose-dependent efficacy. Survival (37%) with 2.5 mg/kg P128 increased to 63% with the P128/vancomycin combination. CONCLUSIONS: P128 exerted a rapid bactericidal effect in vivo and rescued animals from fatal invasive MRSA and VRSA infections. P128/SoC antibiotic combinations exerted a synergistic effect. P128 restored the susceptibility of VRSA to vancomycin. P128 is a novel, potent therapeutic agent for antibiotic-resistant, systemic S. aureus infections.
引用
- Channabasappa S, Chikkamadaiah R, Durgaiah M, et al. Efficacy of chimeric ectolysin P128 in drug-resistant Staphylococcus aureus bacteraemia in mice. J Antimicrob Chemother. 2018. PMID: 30215762. doi:10.1093/jac/dky365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。